Revance's Botox Rival Receives USFDA Nod
By Indu Tyagi Ketan , 19 October, 2022
DaxibotulinumtoxinA (Daxxify), Revance's long-awaited Botox rival, has officially received FDA approval, as the company is now gearing up to establish its brand. Daxxify is an intravenous neuromodulator similar to Botox; its novel peptide exchange technology temporarily eases the moderate to severe glabellar (frown) lines.
The trials revealed that a single injection had a significant anti-wrinkle impact on durational effects were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The chief differentiator for Daxxify is its endurance; it can last six months and has even proven effective for up to nine months in some individuals, vis-a-vis Botox injections that last only for three months.
Daxxify was initially scheduled to receive FDA approval in November 2020, but the epidemic slowed inspection. After visiting Revance's production facility, inspectors discovered quality control and record-keeping issues. The FDA then issued Revance a detailed response letter in October of last year. Soon after, the FDA approved the changes in July after Revance resolved all five problems mentioned in the Complete Response Letter.
Latest News
Globally, nations are investing mindfully in sustainable development to achieve clean energy transition goals in the next three decades. Developed countries like the United States are engaged in sustainable investments. However, the ESG (environment…
Globally, the countries are adopting renewables to go greener by 2050. Countries are focusing on utilizing renewables as their energy source. It is to support the clean energy transition by limiting carbon and other harmful gas emissions. However…
Globally, the countries are adopting renewables to go greener by 2050. Countries are focusing on utilizing renewables as their energy source. It is to support the clean energy transition by limiting carbon and other harmful gas emissions. However…
Chief Strategy Officer